Environmentally-friendly, aqueous concentrated reagent compositions are provided for dilution and use in suitable hematology analyzers for analyzing blood cells including for enumeration and sizing of blood cells, determination of hemoglobin parameters and differentiation of leukocyte subpopulations in a single blood cell sample.

The invention provides gastroenterological cancer determination methods that involve contacting a specimen, an antibody 1 that recognizes an α chain of human haptoglobin, and an antibody 2 that recognizes a β chain of human haptoglobin and does not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 1, or contacting the specimen and two antibodies selected from the antibodies 2 that recognize a β chain of human haptoglobin and do not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 2. A determination is made based on the measurement of complex 1 or 2. Alternatively, the specimen and two antibodies selected from the antibodies 1 that recognize an α chain of human haptoglobin are contacted to form a complex 3, and a determination is made by comparing the measurement results of complex 1 or 2 with complex 3.

The present invention provides for systems and methods for inhaled CO therapy to prevent, attenuate, or delay processes that accelerate the loss of organ or tissue function, thereby increasing the lifespan of transplanted organs or tissues, or slowing the decline of native organs or tissues, or delaying the need for replacement of diseased native organs with organ transplants. Such biological processes that are prevented, attenuated, or delayed include chronic persistent inflammation, fibrosis, scarring, as well as immunologic or autoimmune attack.

A system for testing for an analyte includes a test strip. The test strip includes a first flow path. The test strip further includes a heating element in communication with a heating area of the first flow path, for heating a sample in the first flow path. The test strip further includes an e-gate, the e-gate in the first flow path, the e-gate separating the heating area from a detection area of the first flow path.

A stool resuspension solution comprising a hemoglobin stabilization reagent is provided. In some embodiments, the hemoglobin stabilization reagent may be an osmolyte, a polyvalent cation, a sugar or polysaccharide and, optionally, a polyvalent cation, a protoporphyrin, or an HRP stabilization component and, optionally, a polyvalent cation. A method of stabilizing hemoglobin in a stool sample in the solution is also provided, as well as a sample collection device containing the solution.

Analytical assay reaction cartridges are disclosed that include a reagent tray containing a liquid reagent disposed therein and a flexible cover removably attached thereto. The flexible cover has a portion that extends beyond the reagent tray and that forms a tab portion extends through an opening in a lid member of the cartridge in order to facilitate removal of at least a portion of the cover and release of the liquid reagent. Also disclosed are analytical assay reaction kits that include the cartridges and diagnostic instruments for use with the analytical assay reaction cartridges/kits, as well as methods of making and using the cartridges/kits.

A method for determining analytes includes lysing the red blood cells of a whole blood sample, oxidizing the free hemoglobin in the lysed sample, and cleaving FVH from the hemoglobin A1C to form an electrochemical test solution. In one aspect, a first portion of the electrochemical test solution is reacted with fructosyl peptide oxidase and a reduced ruthenium mediator to form a first reaction product. A first electrical property of the first reaction product is measured, the measurement being indicative of hemoglobin A1C in the blood sample. In another aspect, a second portion of the electrochemical test solution is reacted with ferrocyanide to form a second reaction product. A second electrical property of the second reaction product is measured, the measurement being indicative of total hemoglobin in the blood sample. Hemoglobin A1C, total hemoglobin, and % HbA1C are determined based on the first and second electrical properties.

Provided are a measurement sample diluent that enables the measurement of the proportion of HbA1c in the total Hb molecules in a measurement sample (HbA1c (%)), with high sensitivity, high accuracy, and high correlation with HPLC without being affected by the length of time required to mix a measurement sample with the measurement sample diluent and to drop the mixture onto an immunochromatographic specimen for measuring HbA1c; and a kit containing the measurement sample diluent. The present invention relates to a measurement sample diluent for immunochromatography for quantifying the proportion of hemoglobin A1c in the total hemoglobin molecules in a measurement sample (hemoglobin A1c (%)); and the measurement sample diluent is an aqueous solution that contains a non-ionic surfactant, an anionic surfactant, and a buffer.

The present invention relates to a normalisation method for a dried blood matrix, said method comprising the steps: providing the dried blood matrix, extracting at least one analyte from a first portion of the dried blood matrix and haemoglobin from a second portion of the dried blood matrix, quantitatively analysing the at least one extracted analyte and the extracted haemoglobin, determining a concentration of the at least one analyte in the first portion of the dried blood matrix and a concentration of the haemoglobin in the second portion of the dried blood matrix, deriving the haematocrit of the second portion of the dried blood matrix on the basis of the concentration of the haemoglobin, and calculating a normalisation factor on the basis of the determined haematocrit in order to normalise the concentration of the at least one analyte in the first portion of the dried blood matrix. The invention also relates to a normalisation device (10) for performing a method according to the invention.

An example blood cell lysis composition includes a buffer and a secondary alcohol ethoxylate at a concentration in the range of about 2.5 percent (%) to about 20% weight per volume (w/v). The secondary alcohol ethoxylate may include Tergitol™ TMN-100X or Tergitol™ 15-S-9. The composition may be configured to lyse at least 90% of blood cells in a blood sample.